

Universal Biosensors, Inc.
ARBN 121 559 993

1 Corporate Avenue
Rowville Victoria 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

8 May 2017

Commencement of Xprecia Stride™ Coagulation Analyser sales activities in the US market

Melbourne, Australia: Universal Biosensors (ASX:UBI) is pleased to announce that Siemens Healthineers, has commenced sales activities of the Xprecia Stride™ Coagulation Analyser in the US market.

The Xprecia Stride™ Coagulation Analyser is a handheld device which delivers fast, reliable Prothrombin Time International Normalized Ratio (PT/INR) testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin, a vitamin K antagonist.

The Xprecia Stride™ Coagulation Analyser received US Food and Drug Administration (FDA) clearance for sale in the US in October 2016.

UBI Executive Chairman, Andrew Denver said: “Commencement of sales activities in the US is an important milestone in our collaboration with Siemens. Sales activities are being made for a professional segment of the US market. Siemens is responsible for the sales and marketing and the global roll-out of the Xprecia Stride™ whilst UBI is responsible for the manufacture of the strips.”

ENDS

Enquiries:
Andrew Denver
Saresh Balak
+61 3 9213 9000

Investor
Rebecca Wilson
+61 417 382 391

Media
Amanda Loh
+61 3 8866 1215

About Universal Biosensors

For additional information in relation to Universal Biosensors, refer to <http://www.universalbiosensors.com/announcements.html>.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no

Universal Biosensors, Inc.
ARBN 121 559 993

1 Corporate Avenue
Rowville Victoria 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposed offering will occur, and the terms of any such offering are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.